Clinical and molecular comparison between borderline serous ovarian tumors and advanced serous papillary ovarian carcinomas

R. Halperin, S. Zehavi, Pe'er Dar, L. Habler, E. Hadas, I. Bukovsky, D. Schneider

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The aim of this study was to characterize the clinical and molecular markers of borderline serous ovarian tumors (BSOT), and to study their expression in the progression from benign lesions to advanced serous papillary ovarian carcinomas (SPOC). The clinical records of 20 patients with BSOT and 22 patients with SPOC were reviewed. Specimens from all these cases and from six benign ovarian serous cystadenomas were evaluated for expression of estrogen receptors (ER), progesterone receptors (PR), p53, HER-2/neu and Ki-67 by immunohistochemical techniques. The mean patient age and the age at menarche differed significantly between the compared groups of BSOT and SPOC (p=0.0006 and p=0.0014, respectively). No difference was observed comparing the other clinical parameters. The immunohistochemical analysis demonstrated a significant increase in the expression of ER (100% vs 72.7%), and a significant decrease in the immunoreactivity for p53 (0% vs 45.4%) and Ki-67 (2% vs 26.8%) in cases of BSOT compared with those of SPOC (p=0.007, p=0.0003 and p=0.012, respectively). No significant difference was demonstrated comparing the expression of PR and HER-2/neu. The immunostaining of benign ovarian serous cystadenoma specimens did not differ significantly from immunoreactivity observed in cases of BSOT. According to immunohistochemical analysis, BSOT had much more in common with benign serous tumors than with SPOC. The main difference between BSOT and SPOC was regarding the overexpression of p53 and Ki-67.

Original languageEnglish (US)
Pages (from-to)292-296
Number of pages5
JournalEuropean Journal of Gynaecological Oncology
Volume22
Issue number4
StatePublished - 2001
Externally publishedYes

Fingerprint

Papillary Carcinoma
Neoplasms
Serous Cystadenoma
Progesterone Receptors
Estrogen Receptors
Menarche
Biomarkers

Keywords

  • Benign serous ovarian tumor
  • Borderline serous ovarian tumor
  • Clinical parameters
  • Immunohistochemistry
  • Molecular markers
  • Serous papillary ovarian carcinoma

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Clinical and molecular comparison between borderline serous ovarian tumors and advanced serous papillary ovarian carcinomas. / Halperin, R.; Zehavi, S.; Dar, Pe'er; Habler, L.; Hadas, E.; Bukovsky, I.; Schneider, D.

In: European Journal of Gynaecological Oncology, Vol. 22, No. 4, 2001, p. 292-296.

Research output: Contribution to journalArticle

Halperin, R. ; Zehavi, S. ; Dar, Pe'er ; Habler, L. ; Hadas, E. ; Bukovsky, I. ; Schneider, D. / Clinical and molecular comparison between borderline serous ovarian tumors and advanced serous papillary ovarian carcinomas. In: European Journal of Gynaecological Oncology. 2001 ; Vol. 22, No. 4. pp. 292-296.
@article{bf7a5034fedb475c92ebd0497f57b39f,
title = "Clinical and molecular comparison between borderline serous ovarian tumors and advanced serous papillary ovarian carcinomas",
abstract = "The aim of this study was to characterize the clinical and molecular markers of borderline serous ovarian tumors (BSOT), and to study their expression in the progression from benign lesions to advanced serous papillary ovarian carcinomas (SPOC). The clinical records of 20 patients with BSOT and 22 patients with SPOC were reviewed. Specimens from all these cases and from six benign ovarian serous cystadenomas were evaluated for expression of estrogen receptors (ER), progesterone receptors (PR), p53, HER-2/neu and Ki-67 by immunohistochemical techniques. The mean patient age and the age at menarche differed significantly between the compared groups of BSOT and SPOC (p=0.0006 and p=0.0014, respectively). No difference was observed comparing the other clinical parameters. The immunohistochemical analysis demonstrated a significant increase in the expression of ER (100{\%} vs 72.7{\%}), and a significant decrease in the immunoreactivity for p53 (0{\%} vs 45.4{\%}) and Ki-67 (2{\%} vs 26.8{\%}) in cases of BSOT compared with those of SPOC (p=0.007, p=0.0003 and p=0.012, respectively). No significant difference was demonstrated comparing the expression of PR and HER-2/neu. The immunostaining of benign ovarian serous cystadenoma specimens did not differ significantly from immunoreactivity observed in cases of BSOT. According to immunohistochemical analysis, BSOT had much more in common with benign serous tumors than with SPOC. The main difference between BSOT and SPOC was regarding the overexpression of p53 and Ki-67.",
keywords = "Benign serous ovarian tumor, Borderline serous ovarian tumor, Clinical parameters, Immunohistochemistry, Molecular markers, Serous papillary ovarian carcinoma",
author = "R. Halperin and S. Zehavi and Pe'er Dar and L. Habler and E. Hadas and I. Bukovsky and D. Schneider",
year = "2001",
language = "English (US)",
volume = "22",
pages = "292--296",
journal = "European Journal of Gynaecological Oncology",
issn = "0392-2936",
publisher = "S.O.G. CANADA Inc.",
number = "4",

}

TY - JOUR

T1 - Clinical and molecular comparison between borderline serous ovarian tumors and advanced serous papillary ovarian carcinomas

AU - Halperin, R.

AU - Zehavi, S.

AU - Dar, Pe'er

AU - Habler, L.

AU - Hadas, E.

AU - Bukovsky, I.

AU - Schneider, D.

PY - 2001

Y1 - 2001

N2 - The aim of this study was to characterize the clinical and molecular markers of borderline serous ovarian tumors (BSOT), and to study their expression in the progression from benign lesions to advanced serous papillary ovarian carcinomas (SPOC). The clinical records of 20 patients with BSOT and 22 patients with SPOC were reviewed. Specimens from all these cases and from six benign ovarian serous cystadenomas were evaluated for expression of estrogen receptors (ER), progesterone receptors (PR), p53, HER-2/neu and Ki-67 by immunohistochemical techniques. The mean patient age and the age at menarche differed significantly between the compared groups of BSOT and SPOC (p=0.0006 and p=0.0014, respectively). No difference was observed comparing the other clinical parameters. The immunohistochemical analysis demonstrated a significant increase in the expression of ER (100% vs 72.7%), and a significant decrease in the immunoreactivity for p53 (0% vs 45.4%) and Ki-67 (2% vs 26.8%) in cases of BSOT compared with those of SPOC (p=0.007, p=0.0003 and p=0.012, respectively). No significant difference was demonstrated comparing the expression of PR and HER-2/neu. The immunostaining of benign ovarian serous cystadenoma specimens did not differ significantly from immunoreactivity observed in cases of BSOT. According to immunohistochemical analysis, BSOT had much more in common with benign serous tumors than with SPOC. The main difference between BSOT and SPOC was regarding the overexpression of p53 and Ki-67.

AB - The aim of this study was to characterize the clinical and molecular markers of borderline serous ovarian tumors (BSOT), and to study their expression in the progression from benign lesions to advanced serous papillary ovarian carcinomas (SPOC). The clinical records of 20 patients with BSOT and 22 patients with SPOC were reviewed. Specimens from all these cases and from six benign ovarian serous cystadenomas were evaluated for expression of estrogen receptors (ER), progesterone receptors (PR), p53, HER-2/neu and Ki-67 by immunohistochemical techniques. The mean patient age and the age at menarche differed significantly between the compared groups of BSOT and SPOC (p=0.0006 and p=0.0014, respectively). No difference was observed comparing the other clinical parameters. The immunohistochemical analysis demonstrated a significant increase in the expression of ER (100% vs 72.7%), and a significant decrease in the immunoreactivity for p53 (0% vs 45.4%) and Ki-67 (2% vs 26.8%) in cases of BSOT compared with those of SPOC (p=0.007, p=0.0003 and p=0.012, respectively). No significant difference was demonstrated comparing the expression of PR and HER-2/neu. The immunostaining of benign ovarian serous cystadenoma specimens did not differ significantly from immunoreactivity observed in cases of BSOT. According to immunohistochemical analysis, BSOT had much more in common with benign serous tumors than with SPOC. The main difference between BSOT and SPOC was regarding the overexpression of p53 and Ki-67.

KW - Benign serous ovarian tumor

KW - Borderline serous ovarian tumor

KW - Clinical parameters

KW - Immunohistochemistry

KW - Molecular markers

KW - Serous papillary ovarian carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0034776001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034776001&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 292

EP - 296

JO - European Journal of Gynaecological Oncology

JF - European Journal of Gynaecological Oncology

SN - 0392-2936

IS - 4

ER -